PurMinds Enterprises

PurMinds Enterprises is a precision medicine and neuro-medicine development company building an integrated '4P Medicine' ecosystem (Predictive, Preventive, Personalized, and Participatory) focused on neurological and psychiatric disorders. The company's therapeutic pipeline, housed under its subsidiary PurQuest Therapeutics, includes novel neuroprotective compounds and neuroplastogens, such as PUR501 (a non-hallucinogenic 5-HT2A receptor partial agonist) and PUR102 (a botanical psilocybin formulation). In addition to therapeutics, PurMinds is developing the SwiftLab point-of-care diagnostic platform in partnership with SpectroChip, utilizing photonic chip-based technology for early detection of neurological conditions. Operating a 20,000-square-foot GMP-compliant facility in Ontario, Canada, PurMinds holds a Health Canada Controlled Drugs and Substances License, enabling the production and global supply of pharma-grade controlled substances.